The World Health Organisation (WHO) has categorised the JN.1 COVID pressure as a “variant of interest”.
Announcing the brand new classification, the UN company burdened the danger posed by the pressure is taken into account “low”.
“Based on the available evidence, the additional global public health risk posed by JN.1 is currently evaluated as low,” WHO mentioned.
It mentioned current vaccines continued to be efficient in opposition to extreme illness and dying from JN.1 and different circulating variants.
The classification comes as COVID instances rise within the UK within the run-up to Christmas.
The newest knowledge, which covers the week ending 9 December, exhibits COVID instances rising by 39% in England on the earlier week.
Read extra on Sky News:
COVID instances are rising – what if I catch it at Christmas?
COVID: Almost 40% of over-65s not but taken booster jab for Christmas
People faraway from COVID inquiry as Boris Johnson apologises
JN.1 is a sub-lineage of the BA.2.86 Omicron variant.
It has one mutation in its spike protein – which dictates how simply it might probably infect our cells – in comparison with BA.2.86. But there are a number of different mutations elsewhere.
Speaking to Sky News earlier this month, Professor of innate immunity on the University of Cambridge, Clare Bryant, mentioned the adjustments have been more likely to imply JN.1 evades our immune methods extra simply – and replicates sooner.
“The change in the spike protein will probably correlate to it being more infectious,” she mentioned.
However, there has thus far been no indication of elevated illness severity, in keeping with Professor Nicolas Locker, a virologist on the Pirbright Institute.
“I think we’re just seeing the natural evolution of COVID and I don’t think there’s anything right now we should be overly worried about,” he mentioned.
“These are very small changes in comparison to the ones between Omicron and the previous set of variants. And we haven’t seen a change in symptoms or severity.”
According to the US Centers for Disease Control and Prevention’s (CDC) newest projections, JN.1 presently makes up an estimated 15% – 29% of instances within the UK.
Source: information.sky.com”